UPDATE: Sanofi (SNY), Regeneron (REGN) Report CHMP Recommends Approval of Praluent (alirocumab) to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Sanofi (NASDAQ: SNY) and Regeneron (NASDAQ: REGN) announce the European Medicines ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)